Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs. / Osborn, Mark J.; Newby, Gregory A.; McElroy, Amber N.; Knipping, Friederike; Nielsen, Sarah C.; Riddle, Megan J.; Xia, Lily; Chen, Weili; Eide, Cindy R.; Webber, Beau R.; Wandall, Hans H.; Dabelsteen, Sally; Blazar, Bruce R.; Liu, David R.; Tolar, Jakub.
In: Journal of Investigative Dermatology, Vol. 140, No. 2, 2020, p. 338-347.e5.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs
AU - Osborn, Mark J.
AU - Newby, Gregory A.
AU - McElroy, Amber N.
AU - Knipping, Friederike
AU - Nielsen, Sarah C.
AU - Riddle, Megan J.
AU - Xia, Lily
AU - Chen, Weili
AU - Eide, Cindy R.
AU - Webber, Beau R.
AU - Wandall, Hans H.
AU - Dabelsteen, Sally
AU - Blazar, Bruce R.
AU - Liu, David R.
AU - Tolar, Jakub
PY - 2020
Y1 - 2020
N2 - Genome editing represents a promising strategy for the therapeutic correction of COL7A1 mutations that cause recessive dystrophic epidermolysis bullosa (RDEB). DNA cleavage followed by homology-directed repair (HDR) using an exogenous template has previously been used to correct COL7A1 mutations. HDR rates can be modest, and the double-strand DNA breaks that initiate HDR commonly result in accompanying undesired insertions and deletions (indels). To overcome these limitations, we applied an A•T→G•C adenine base editor (ABE) to correct two different COL7A1 mutations in primary fibroblasts derived from RDEB patients. ABE enabled higher COL7A1 correction efficiencies than previously reported HDR efforts. Moreover, ABE obviated the need for a repair template, and minimal indels or editing at off-target sites was detected. Base editing restored the endogenous type VII collagen expression and function in vitro. We also treated induced pluripotent stem cells (iPSCs) derived from RDEB fibroblasts with ABE. The edited iPSCs were differentiated into mesenchymal stromal cells, a cell population with therapeutic potential for RDEB. In a mouse teratoma model, the skin derived from ABE-treated iPSCs showed the proper deposition of C7 at the dermal–epidermal junction in vivo. These demonstrate that base editing provides an efficient and precise genome editing method for autologous cell engineering for RDEB.
AB - Genome editing represents a promising strategy for the therapeutic correction of COL7A1 mutations that cause recessive dystrophic epidermolysis bullosa (RDEB). DNA cleavage followed by homology-directed repair (HDR) using an exogenous template has previously been used to correct COL7A1 mutations. HDR rates can be modest, and the double-strand DNA breaks that initiate HDR commonly result in accompanying undesired insertions and deletions (indels). To overcome these limitations, we applied an A•T→G•C adenine base editor (ABE) to correct two different COL7A1 mutations in primary fibroblasts derived from RDEB patients. ABE enabled higher COL7A1 correction efficiencies than previously reported HDR efforts. Moreover, ABE obviated the need for a repair template, and minimal indels or editing at off-target sites was detected. Base editing restored the endogenous type VII collagen expression and function in vitro. We also treated induced pluripotent stem cells (iPSCs) derived from RDEB fibroblasts with ABE. The edited iPSCs were differentiated into mesenchymal stromal cells, a cell population with therapeutic potential for RDEB. In a mouse teratoma model, the skin derived from ABE-treated iPSCs showed the proper deposition of C7 at the dermal–epidermal junction in vivo. These demonstrate that base editing provides an efficient and precise genome editing method for autologous cell engineering for RDEB.
U2 - 10.1016/j.jid.2019.07.701
DO - 10.1016/j.jid.2019.07.701
M3 - Journal article
C2 - 31437443
AN - SCOPUS:85075115915
VL - 140
SP - 338-347.e5
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
SN - 0022-202X
IS - 2
ER -
ID: 236668530